[1] Wang, K, Gill P, Perera R, et al. Clinical symptoms and signs for the diagnosis of Mycoplasma pneumoniae in children and adolescents with community-acquired pneumonia. Cochrane Database Syst Rev, 2012; 10, CD009175.
[2] Jain S, Williams DJ, Arnold SR, et al. Community-Acquired Pneumonia Requiring Hospitalization among U.S. Children. N Engl J Med, 2015; 372, 835−45.
[3] Liu WK, Liu Q, Chen DH, et al. Epidemiology of Acute Respiratory Infections in Children in Guangzhou: A Three-Year Study. PLoS One, 2014; 9, e96674.
[4] Yang TI, Chang TH, Lu CY, et al. Mycoplasma pneumoniae in pediatric patients: Do macrolide-resistance and/or delayed treatment matter? J Microbiol Immunol Infect, 2019; 52, 329−35.
[5] Curtiss, P, Melnick L, Sicco KL, et al. Mycoplasma pneumoniae, more than a lung disease. Dermatol Online J, 2018; 24, 13030/qt8w993185.
[6] Ma LD, Chen B, Dong Y, et al. Rapid mycoplasma culture for the early diagnosis of Mycoplasma pneumoniae infection. J Clin Lab Anal, 2010; 24, 224−9.
[7] Cécile Bébéar, Sabine Pereyre, Olivia Peuchant. Mycoplasma pneumoniae: susceptibility and resistance to antibiotics. Future Microbiology, 2011; 6, 423−31.
[8] Yang HJ. Benefits and risks of therapeutic alternatives for macrolide resistant Mycoplasma pneumoniae pneumonia in children. Korean J Pediatr, 2019; 62, 199−205.
[9] Kawai Y, Miyashita N, Kubo M, et al. Nationwide Surveillance of Macrolide-Resistant Mycoplasma pneumoniae Infection in Pediatric Patients. Antimicrob Agents Chemother, 2013; 57, 4046−9.
[10] Dégrange S, Cazanave C, Charron A, et al. Development of Multiple-Locus Variable-Number Tandem-Repeat Analysis for Molecular Typing of Mycoplasma pneumoniae. J Clin Microbiol, 2009; 47, 914−23.
[11] Waites KB, Xiao L, Liu Y, et al. Mycoplasma pneumoniae from the Respiratory Tract and Beyond. Clin Microbiol Rev, 2017; 30, 747−809.
[12] Taylor-Robinson D. Infections due to species of Mycoplasma and Ureaplasma: an update. Clin Infect Dis, 1996; 23, 671−82.
[13] Diaz MH, Winchell JM. Winchell, The Evolution of Advanced Molecular Diagnostics for the Detection and Characterization of Mycoplasma pneumoniae. Front Microbiol, 2016; 7, 232.
[14] Sasaki T, Kenri T, Okazaki N, et al. Epidemiological study of Mycoplasma pneumoniae infections in japan based on PCR-restriction fragment length polymorphism of the P1 cytadhesin gene. J Clin Microbiol, 1996; 34, 447−9.
[15] Kenri T, Okazaki N, Yamazaki T, et al. Genotyping analysis of Mycoplasma pneumoniae clinical strains in Japan between 1995 and 2005: type shift phenomenon of M. pneumoniae clinical strains. J Med Microbiol, 2008; 57, 469−75.
[16] Oishi T, Takahashi K, Wakabayashi S, et al. Comparing Antimicrobial Susceptibilities among Mycoplasma pneumoniae Isolates from Pediatric Patients in Japan between Two Recent Epidemic Periods. Antimicrob Agents Chemother, 2019; 63, e02517−18.
[17] Katsukawa C, Kenri T, Shibayama K, et al. Genetic characterization of Mycoplasma pneumoniae isolated in Osaka between 2011 and 2017: Decreased detection rate of macrolide-resistance and increase of p1 gene type 2 lineage strains. PLoS One, 2019; 14, e0209938.
[18] Guo DX, Hu WJ, Li D, et al. Development of real-time fluorescence quantitative PCR for the detection of Mycoplasma pneumoniae. Infectious Disease Information, 2016; 29, 52−6. (In Chinese)
[19] Liu X, Jiang Y, Chen XG, et al. Drug Resistance Mechanisms of Mycoplasma pneumoniae to Macrolide Antibiotics. Biomed Res Int, 2014; 2014, 320801.
[20] Tian XJ, Dong YQ, Dong XP, et al. P1 gene of Mycoplasma pneumoniae in clinical isolates collected in Beijing in 2010 and relationship between genotyping and macrolide resistance. Chin Med J (Engl), 2013; 126, 3944−8.
[21] Waites KB, Bade DJ, Bébéar C, et al. Methods for Antimicrobial Susceptibility Testing for Human Mycoplasmas; Approved Guideline. CLSI Standards: Guidelines for Health Care Excellence. 2011, Wayne (PA): Clinical and Laboratory Standards Institute. Report No.: M43-A.
[22] Chalker VJ, Pereyre S, Dumke R, et al. International mycoplasma pneumoniae typing study: interpretation of m. pneumoniae multilocus variable-number tandem-repeat analysis. New Microbes New Infect, 2015; 7, 37−40.
[23] Okazaki N, Narita M, Yamada S, et al. Characteristics of macrolide-resistant Mycoplasma pneumoniae strains isolated from patients and induced with erythromycin in vitro. Microbiol Immunol, 2001; 45, 617−20.
[24] Dumke R, Stolz S, Jacobs E, et al. Molecular characterization of macrolide resistance of a Mycoplasma pneumoniae strain that developed during therapy of a patient with pneumonia. Int J Infect Dis, 2014; 29, 197−9.
[25] Xin DL, MI ZH, Han X, et al. Molecular mechanisms of erythromycin resistance in mycoplasma pneumonia. Journal of applied clinical pediatrics, 2005; 20, 666−7. (In Chinese)
[26] Pereyre S, Charron A, Renaudin H, et al. First report of macrolide-resistant strains and description of a novel nucleotide sequence variation in the P1 adhesin gene in Mycoplasma pneumoniae clinical strains isolated in France over 12 years. J Clin Microbiol, 2007; 45, 3534−9.
[27] Dumke R, Von BH, Lück PC, et al. Occurrence of macrolide-resistant Mycoplasma pneumoniae strains in Germany. Clin Microbiol Infect, 2010; 16, 613−6. doi:  10.1111/j.1469-0691.2009.02968.x
[28] Almasri M, Diza E, Papa A, et al. Mycoplasma pneumoniae respiratory tract infections among Greek children. Hippokratia, 2011; 15, 147−52.
[29] Maffeis L, Dilena R, Guez S, et al. Pseudotumour cerebri associated with mycoplasma pneumoniae infection and treatment with levofloxacin: a case report. BMC Pediatr, 2019; 19, 4.
[30] Rodriguez N, Mondeja B, Sardiñas R, et al. First detection and characterization of macrolide-resistant Mycoplasma pneumoniae strains in Cuba. Int J Infect Dis, 2019; 80, 115−7.
[31] Lu CY, Yen TY, Chang LY. Multiple-locus variable-number tandem-repeat analysis (MLVA) of macrolide-susceptible and -resistant Mycoplasma pneumoniae in children in Taiwan. J Formos Med Assoc, 2020; 119, 1539−45.
[32] Liu Y, Ye X, Zhang H, et al. Characterization of macrolide resistance in Mycoplasma pneumoniae isolated from children in Shanghai, China. Diagn Microbiol Infect Dis, 2010; 67, 355−8. (In Chinese)
[33] Diaz MH, Benitez AJ, Cross KE, et al. Molecular detection and characterization of Mycoplasma pneumoniae among patients hospitalized with community-acquired pneumonia in the United States. Open Forum Infect Dis, 2015; 2, ofv106.
[34] Diaz MH, Benitez AJ, Winchell JM. Investigations of Mycoplasma pneumoniae infections in the United States: trends in molecular typing and macrolide resistance from 2006 to 2013. J Clin Microbiol, 2015; 53, 124−30.
[35] Pereyre S, Goret J, Bébéar C. Mycoplasma pneumoniae: Current knowledge on macrolide resistance and treatment. Front Microbiol, 2016; 7, 974.
[36] Satu K, Mirja P, Kati H, et al. Mycoplasma Pneumoniae Outbreak, Southeastern Finland, 2017-2018: Molecular Epidemiology and Laboratory Diagnostic Lessons. Eur J Clin Microbiol Infect Dis, 2019; 38, 1867−71.
[37] Itagaki T, Suzuki Y, Seto J, et al. Two cases of macrolide resistance in Mycoplasma pneumoniae acquired during the treatment period. J Antimicrob Chemother, 2013; 68, 724−5.
[38] Cardinale F, Chironna M, Dumke R, et al. Macrolide-resistant mycoplasma pneumoniae in paediatric pneumonia. Eur Respir J, 2011; 37, 1522−4.
[39] Chou CC, Shen CF, Chen SJ, et al. Recommendations and guidelines for the treatment of pneumonia in Taiwan. J Microbiol Immunol Infect, 2019; 52, 172−99. (In Chinese)
[40] Infectious Diseases Group, Respiratory Disease Branch of Chinese Medical Association. Expert consensus on diagnosis and treatment of adult Mycoplasma pneumoniae pneumonia. Chinese Journal of Tuberculosis and Respiratory Diseases, 2010; 33, 643−5. (In Chinese) doi:  10.3760/cma.j.issn.1001-0939.2010.09.002
[41] The committee of Japanese Society of Mycoplasmology. Guiding principles for treating Mycoplasma pneumoniae pneumonia. 5(23), 2014. (In Japanese)
[42] Respiratory Branch of Chinese Pediatric Society of Chinese Medical Association, Editorial Board of Chinese Journal of Applied Clinical Pediatrics. Expert consensus on diagnosis and treatment of mycoplasma pneumoniae pneumonia in children (2015). Chinese Journal of Applied Clinical Pediatrics.30(), 2015, 09.1304-8. (In Chinese)
[43] Guangdong Pharmaceutical Association. Expert consensus on the application of fluoroquinolone antibacterial drugs in children. Pharmacy Today, 2018.01.1-10. Doi:10.12048/j.issn.1674-229X.2018.01.001.(In Chinese)
[44] Yan C, Sun H, Lee S, et al. Comparison of Molecular Characteristics of Mycoplasma pneumoniae Specimens Collected from the United States and China. J Clin Microbiol, 2015; 53, 3891−3.
[45] Suzuki Y, Seto J, Shimotai Y, et al. Multiple-Locus Variable-Number Tandem-Repeat Analysis of Mycoplasma pneumoniae Isolates between 2004 and 2014 in Yamagata, Japan: Change in Molecular Characteristics during an 11-year Period. Jpn J Infect Dis, 2017; 70, 642−6.
[46] Qu J, Chen S, Bao F, et al. Molecular characterization and analysis of Mycoplasma pneumoniae among patients of all ages with community-acquired pneumonia during an epidemic in China. Int J Infect Dis, 2019; 83, 26−31.
[47] Benitez AJ, Diaz MH, Wolff BJ, et al. Multilocus variable-number tandem-repeat analysis of Mycoplasma pneumoniae clinical isolates from 1962 to the present: a retrospective study. J Clin Microbiol, 2012; 50, 3620−6.
[48] Sun H, Xue G, Yan C, et al. Changes in Molecular Characteristics of Mycoplasma pneumoniae in Clinical Specimens from Children in Beijing between 2003 and 2015. PLoS One, 2017; 12, e0170253.
[49] Voronina EN, Gordukova MA, Turina IE, et al. Molecular characterization of Mycoplasma pneumoniae infections in Moscow from 2015 to 2018. Eur J Clin Microbiol Infect Dis, 2020; 39, 257−63.
[50] Zhao F, Liu J, Shi W, et al. Antimicrobial susceptibility and genotyping of Mycoplasma pneumoniae isolates in Beijing, China, from 2014 to 2016. Antimicrob Resist Infect Control, 2019; 8, 18.